CLEVELAND - Abeona Therapeutics Inc. (NASDAQ:ABEO) announced the appointment of Keith A. Goldan as an independent member of its Board of Directors, effective April 1, according to a press release statement. The appointment comes as the company, with a market capitalization of $271.84 million, trades at $4.76 per share.
Goldan will serve as Chairman of the company's Audit Committee. He brings over 20 years of financial leadership experience in publicly traded biotechnology and pharmaceutical companies.
Goldan currently serves as Chief Financial Officer of Syndax Pharmaceuticals, a position he has held since 2022. In that role, he has overseen the company through two product approvals and commercialization. He previously served as CFO at Optinose, where he supported the U.S. launch of the company's lead product, and at Fibrocell, a cell and gene therapy company.
His earlier CFO roles include positions at NuPathe, PuriCore plc, and Biosyn. Goldan also held financial leadership positions at ViroPharma and KPMG. Throughout his career, he has led finance, accounting, IT, human resources, and corporate development functions and has participated in multiple initial public offerings and merger and acquisition transactions.
"Keith's deep experience in capital markets, corporate development, and operational scaling will be an invaluable voice as we continue to position Abeona for growth as a commercial-stage biotech company," said Michael Amoroso, Chairman of Abeona's Board of Directors.
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies. The company's ZEVASKYN is an autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa. The company operates a manufacturing facility in Cleveland, Ohio for ZEVASKYN commercial production.
According to InvestingPro analysis, Abeona appears undervalued at current levels, with analysts forecasting 10% revenue growth this year. The company maintains a strong balance sheet with more cash than debt and a current ratio of 6.93.
In other recent news, Abeona Therapeutics reported its first commercial revenue in the fourth quarter of 2025, achieving a total revenue of $5.8 million for the year. This milestone follows the FDA approval of its gene therapy, ZEVASKYN, and the revenue figure surpassed initial forecasts. Oppenheimer reiterated an Outperform rating for Abeona Therapeutics, maintaining a $22.00 price target, following the company's year-end financial results and business update. The company disclosed that one patient was treated with ZEVASKYN in 2025, with an additional treatment already conducted in 2026. Stifel, however, lowered its price target for Abeona Therapeutics to $17 from $19 while maintaining a Buy rating due to revised sales estimates for ZEVASKYN. Stifel's projections now anticipate a second-half 2026 weighted cadence of treated patients, estimating three patients treated in the first quarter of 2026. These developments highlight ongoing investor interest and analysis of Abeona Therapeutics' performance and future potential.